Inventor · disambiguated record
Mark Yamanaka
Also filed as: YAMANAKA MARK
15 granted patents·7 pending applications·138 citations·filing 2007–2025
94Inventor score
Top patents by PatentIndex Score
22 records- 0198US11001630B2Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted May 11, 2021·10 cites·20 claims
- 0298US10988536B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted Apr 27, 2021·10 cites·20 claims
- 0398US10344089B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2017·Granted Jul 9, 2019·25 cites·20 claims
- 0497US11530267B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Dec 20, 2022·2 cites·21 claims
- 0597US11236165B2Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 0697US11236163B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 0797US11236164B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 0896US11512130B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Nov 29, 2022·2 cites·22 claims
- 0996US10988535B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Granted Apr 27, 2021·10 cites·20 claims
- 1090US8680247B2Monoclonal antibodies against glypican-3TERRETT JONATHAN ALEXANDER·Filed 2008·Granted Mar 25, 2014·23 cites·21 claims
- 1190US8481683B2Human antibodies that bind CD22 and uses thereofKING DAVID JOHN·Filed 2007·Granted Jul 9, 2013·31 cites·20 claims
- 1286US9499632B2Human antibodies that bind CD22 and uses thereofSQUIBB & SONS LLC·Filed 2013·Granted Nov 22, 2016·8 cites·42 claims
- 1386US2023322919A1Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses ThereofSQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 1482US8039596B2Alpha 5-beta 1 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Oct 18, 2011·4 cites·10 claims
- 1580US2025154254A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2025·Application pending·0 cites
- 1674US2020231671A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 1772US2011150892A1Human antibodies that bind lymphocyte activation gene-3 (lag-3) and uses thereofMEDAREX INC·Filed 2009·Application pending·0 cites
- 1869US9217033B2Monoclonal antibodies against Glypican-3SQUIBB & SONS LLC·Filed 2014·Granted Dec 22, 2015·1 cites·9 claims
- 1954US2014154268A1Alpha5-beta1 antibodies and their usesPFIZER·Filed 2013·Application pending·0 cites
- 2050US2017058031A1Human antibodies that bind cd22 and uses thereofSQUIBB & SONS LLC·Filed 2016·Application pending·0 cites
- 2149US8399647B2Alpha5-beta1 antibodies and their usesBENDER STEVEN L·Filed 2011·Granted Mar 19, 2013·0 cites·8 claims
- 2248US2010150950A1Human antibodies that bind cd70 and uses thereofMEDAREX INC·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Yamanaka files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →